Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases

@article{Brettschneider2009SerumAI,
  title={Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases},
  author={J. Brettschneider and T. Jaskowski and H. Tumani and Sana Abdul and J. Rose},
  journal={Journal of Neuroimmunology},
  year={2009},
  volume={217},
  pages={95-101}
}
  • J. Brettschneider, T. Jaskowski, +2 authors J. Rose
  • Published 2009
  • Medicine
  • Journal of Neuroimmunology
  • The serum level of IgM antibodies against Glc(alpha1,4)Glc(alpha) (GAGA4) is higher in relapsing remitting multiple sclerosis (RRMS) compared to other neurological disease (OND) patients and healthy controls (HC). Detecting the level of anti-GAGA4 antibody by enzyme immunoassay and total IgM, we confirmed that anti-GAGA4 IgM can differentiate RRMS from OND patients and HC. Moreover, secondary progressive MS (SPMS) and RRMS patients have similar levels of anti-GAGA4 demonstrating the biomarker's… CONTINUE READING
    31 Citations
    Targets of the humoral autoimmune response in multiple sclerosis.
    • 69
    • Highly Influenced
    Immunological differences between classical phenothypes of multiple sclerosis
    • 28

    References

    SHOWING 1-10 OF 32 REFERENCES
    Serum anti-Glc(α1,4)Glc(α) antibodies as a biomarker for relapsing–remitting multiple sclerosis
    • 48
    • Highly Influential
    Lack of association between antimyelin antibodies and progression to multiple sclerosis.
    • 146
    Clinically isolated syndromes
    • 130
    IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
    • 1,784
    • PDF